Jacobs & Co. CA increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 0.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,904 shares of the medical research company’s stock after buying an additional 292 shares during the period. Jacobs & Co. CA’s holdings in Amgen were worth $9,679,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. Morgan Stanley raised its stake in Amgen by 13.8% in the 4th quarter. Morgan Stanley now owns 9,745,556 shares of the medical research company’s stock valued at $2,240,698,000 after purchasing an additional 1,179,665 shares during the last quarter. Norges Bank acquired a new position in Amgen in the 4th quarter valued at about $1,302,778,000. Aristotle Capital Management LLC raised its stake in Amgen by 5.5% in the 4th quarter. Aristotle Capital Management LLC now owns 4,395,783 shares of the medical research company’s stock valued at $1,006,606,000 after purchasing an additional 227,873 shares during the last quarter. UBS Asset Management Americas Inc. raised its stake in Amgen by 2.1% in the 4th quarter. UBS Asset Management Americas Inc. now owns 3,418,659 shares of the medical research company’s stock valued at $786,018,000 after purchasing an additional 71,386 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Amgen by 0.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,779,593 shares of the medical research company’s stock valued at $639,084,000 after purchasing an additional 23,212 shares during the last quarter. Institutional investors and hedge funds own 75.23% of the company’s stock.
Several research analysts recently weighed in on AMGN shares. Morgan Stanley boosted their target price on shares of Amgen from $277.00 to $279.00 and gave the company an “overweight” rating in a research note on Thursday, March 11th. Oppenheimer boosted their target price on shares of Amgen from $266.00 to $275.00 in a research note on Monday. Piper Sandler dropped their price objective on shares of Amgen from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, February 3rd. Daiwa Capital Markets assumed coverage on shares of Amgen in a research note on Tuesday, December 29th. They set a “buy” rating and a $300.00 price objective for the company. Finally, Royal Bank of Canada reaffirmed a “neutral” rating on shares of Amgen in a research note on Monday, January 4th. Ten research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $258.57.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Monday, February 1st. The medical research company reported $3.81 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.39 by $0.42. The firm had revenue of $6.63 billion during the quarter, compared to analysts’ expectations of $6.57 billion. Amgen had a return on equity of 95.55% and a net margin of 29.42%. Amgen’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.64 EPS. As a group, sell-side analysts expect that Amgen Inc. will post 16.15 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 8th. Stockholders of record on Monday, May 17th will be paid a dividend of $1.76 per share. This represents a $7.04 annualized dividend and a dividend yield of 2.84%. The ex-dividend date of this dividend is Friday, May 14th. Amgen’s dividend payout ratio (DPR) is currently 47.50%.
In other news, EVP Jonathan P. Graham sold 11,110 shares of the stock in a transaction that occurred on Thursday, February 4th. The stock was sold at an average price of $236.51, for a total transaction of $2,627,626.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronald D. Sugar sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 10th. The shares were sold at an average price of $238.40, for a total value of $238,400.00. Following the transaction, the director now owns 16,805 shares of the company’s stock, valued at $4,006,312. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 14,360 shares of company stock valued at $3,393,044. Company insiders own 0.36% of the company’s stock.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Featured Article: What is a Buy-Side Analyst?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.